CELG: Summary for Celgene Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:40am EST - Canadian Markets open in 3 hours and 50 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Celgene Corporation (CELG)

On Feb 9: 55.50 USD 0.00 (0.00%)

MORE ON CELG

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Celgene Corporation (NasdaqNM:CELG) Delayed quote data

Last Trade:	55.50 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	55.50
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	72.41

Day's Range:	N/A - N/A
52wk Range:	36.90 - 59.67
Volume:	0
Avg Vol (3m):	3,835,570
Market Cap:	25.51B
P/E (ttm):	132.46
EPS (ttm):	0.42
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add CELG to Portfolio

Download Data

HEADLINES

•	You'll Become a Millionaire -- Here's When
	at Motley Fool (Mon, Feb 8)

•	The Stocks With the Most Potential
	at Motley Fool (Thu, Feb 4)

•	Onyx and FDA agree on cancer drug study design
	AP (Tue, Feb 2)

•	In Cautionary Mode: Overweight Tech, Healthcare, Consumer Staples, Emerging /Frontier Markets
	at Seeking Alpha (Tue, Feb 2)

•	'Fast Money' Recap: Rally Worries
	at TheStreet.com (Mon, Feb 1)

•	Big Week For Pharma
	at CNBC (Mon, Feb 1)

•	New Star Analyst Rankings for Celgene Corporation
	StarMine (Sat, Jan 30)

•	Loosen Up, Tightwads!
	at Barrons.com (Sat, Jan 30)

•	Wake Up! You Still Have to Pay Attention
	at Motley Fool (Fri, Jan 29)

•	Celgene Beats Zacks Estimate
	Zacks.com (Fri, Jan 29)

•	1-Star Stocks Poised to Plunge: Cytori Therapeutics?
	at Motley Fool (Fri, Jan 29)

•	Celgene Corporation Q4 2009 Earnings Call Transcript
	at Seeking Alpha (Thu, Jan 28)

More Headlines for CELG...

ANALYST

EPS Est (next year) (Dec-08) :	1.53
EPS Est (in 2 years) (Dec-09) :	2.23
Avg Rec (current)*:	1.7
PEG Ratio:	1.02

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•